Micafungine Hikma (Micafungin)

Micafungin is an echinocandin antifungal used to treat systemic Candida infections and related conditions.

• Invasive candidiasis: effective treatment of bloodstream and deep‑tissue Candida infections.
• Esophageal candidiasis: resolves mucosal infection and associated symptoms.
• Prophylaxis in hematopoietic stem cell transplantation: prevents invasive fungal disease in high‑risk transplant recipients.

• Micafungin inhibits the enzyme β-(1,3)-D-glucan synthase, which is essential for synthesizing β-(1,3)-D-glucan, a critical component of the fungal cell wall. By disrupting cell‑wall formation, the drug exerts a fungicidal effect against susceptible Candida species, leading to cell lysis and death.

Micafungin may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Fever: transient temperature elevation during infusion.
• Nausea: mild gastrointestinal upset.
• Vomiting: occasional emesis.
• Headache: mild to moderate intensity.
• Infusion‑related reactions: flushing, chills, or erythema.
• Elevated liver enzymes: transient increase in ALT/AST.

Serious or Rare Side Effects

• Hepatic failure: rare but potentially life‑threatening liver injury.
• Severe hypersensitivity: including anaphylaxis.
• Renal impairment: acute kidney injury in susceptible patients.
• Severe neutropenia: marked reduction in neutrophil count.
• Stevens‑Johnson syndrome: rare severe skin reaction.
• Cardiovascular events: hypotension or arrhythmia during rapid infusion.

When using Micafungine Hikma, clinicians should observe several safety measures.

• Renal function: monitor serum creatinine and adjust therapy if impairment occurs.
• Hepatic function: assess baseline liver enzymes and repeat monitoring during treatment.
• Drug interactions: review concomitant medications, especially CYP inducers or inhibitors.
• Pregnancy and lactation: use only if the potential benefit justifies the potential risk to the fetus or infant.
• Infusion monitoring: administer under medical supervision and watch for infusion‑related reactions.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with several drug classes; awareness of interaction severity guides management.

Major Interactions (Avoid)

• Cytochrome P450 inducers (e.g., rifampin): may markedly reduce micafungin exposure.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): can increase micafungin plasma levels.
• Co‑administration with other echinocandins: raises risk of additive toxicity.

Moderate Interactions (Monitor Closely)

• Azole antifungals (e.g., fluconazole): may have additive antifungal effect; monitor efficacy.
• Immunosuppressants (e.g., tacrolimus, cyclosporine): monitor drug levels for possible elevation.
• Warfarin: observe INR for potential anticoagulation changes.